Exosomal ciRS-122 from oxaliplatin-resistant CRC cells can be delivered to sensitive cells and target miR-122 to increase PKM2 expression levels, further promoting glycolysis and drug resistance (Fig. 2 and Table 1) [71]. Here, PKM is linked to colorectal carcinoma.